Euro
USD
British Pound
NULL
Product Description
Canertinib is an irreversible tyrosine kinase inhibitor. It not only inhibits tyrosine phosphorylation but also enhances ubiquitinylation and accelerates endocytosis and subsequent intracellular destruction of ErbB-2 molecules. Canertinib alkylates a cysteine residue specific to ErbB receptors. The degradative pathway of ErbB receptor tyrosine kinases stimulated by tyrosine kinase inhibitors appears to be chaperone mediated, and thus is similar to the pathways activated by the heat shock protein 90 (Hsp90) antagonist geldanamycin and by stress-induced mechanisms.
Canertinib (CI-1033) is is an orally bioavailable irreversible Pan-erbB tyrosine kinase inhibitor, targeting EGFR with IC50 of 0.8, 19 and 7 nM for EGFR, HER-2 and ErbB-4, respectively.
Biovision | 1617 | Canertinib (CI-1033, PD-183805) DataSheet
Alternate Name/Synonyms: CI-1033, PD-183805, PD 183805
Appearance: Off-white to pale green solid
Formulation: N/A
CAS Number: 289499-45-2
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₂₄H₂₅ClFN₅O₃ . 2HCl
Molecular Weight: 558.86
Cell-Permeable?: Yes
Purity: ≥99%
Solubilities: DMSO (100 mg/ml)
Handling: Protect from air and moisture
Country of Origin: USA
Tag Line: An ErbB receptor tyrosine kinase inhibitor
MDL Number: MFCD09954112
PubChem CID: 156413
SMILES: C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4.Cl.Cl
InChi: InChI=1S/C24H25ClFN5O3.2ClH/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16;;/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29);2*1H
InChi Key: JZZFDCXSFTVOJY-UHFFFAOYSA-N
